

**Feldmann, Heinrich (NIH/NIAID) [E]**

---

**From:** Feldmann, Heinrich (NIH/NIAID) [E]  
**Sent:** Friday, October 03, 2014 3:03 PM  
**To:** 'Casey, Erin D'; Seydou Doumbia  
**Cc:** Sangare, Djibril; Koita, Ousmane; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]  
**Subject:** RE: Laboratory questions

**RELEASE IN FULL**

The assays are the same that the NHI/CDC team uses in Monrovia to support ELWA3 (MSF ward). They target L, NP and GP.

NIH (RML) provided the equipment and training in agreement with CDC-Atlanta.

The first 14 samples were all confirmed by CDC-Atlanta.

**From:** Casey, Erin D [mailto:CaseyED@state.gov]  
**Sent:** Friday, October 03, 2014 12:37 PM  
**To:** Seydou Doumbia  
**Cc:** Sangare, Djibril; Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]  
**Subject:** RE: Laboratory questions

Dean Seydou:

Thanks so much for the email and the assistance. I welcome any additional information regarding the type of test and cross checking results. As I mentioned, I am communicating with US government colleagues so we can best coordinate support for the Ebola response in neighboring countries.

I look forward to seeing you again later this month during our next visit to Bamako.

All the best,  
Erin

Erin D. Casey, MS, DVM  
Program Officer  
Biosecurity Engagement Program  
U.S. Department of State  
(202) 736-4821

**REVIEW AUTHORITY: Sharon Ahmad, Senior Reviewer**

This email is UNCLASSIFIED.

**From:** Seydou Doumbia [mailto:sdoumbi@icermali.org]  
**Sent:** Thursday, October 02, 2014 9:09 PM  
**To:** Casey, Erin D

**Feldmann, Heinrich (NIH/NIAID) [E]**

**From:** Casey, Erin D <CaseyED@state.gov>  
**Sent:** Monday, October 06, 2014 1:17 PM  
**To:** Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Seydou Doumbia  
**Cc:** Sangare, Djibril; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]  
**Subject:** RE: Laboratory questions

RELEASE IN PART B6

Dear colleagues,

Thank you all for this helpful information – much appreciated! I look forward to our continued collaboration.

Best,  
Erin

Erin D. Casey, MS, DVM  
Program Officer  
Biosecurity Engagement Program  
U.S. Department of State  
(202) 736-4821

This email is UNCLASSIFIED.

REVIEW AUTHORITY: Sharon Ahmad, Senior  
Reviewer

**From:** Ousmane Koita [mailto: ]  
**Sent:** Saturday, October 04, 2014 7:24 AM  
**To:** Feldmann, Heinrich (NIH/NIAID) [E]; Casey, Erin D; Seydou Doumbia  
**Cc:** Djibril Sangare; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]  
**Subject:** RE: Laboratory questions

B6

Thanks Prof Heinz, so far we have tested 22 suspected cases using the screening assay and the confirmatory RT-PCR. All were negative

Erin, I hope to see you during your coming visit here in Mali.

Best regards,

Ousmane

**From:** Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]  
**Sent:** Friday, October 03, 2014 9:03 PM  
**To:** 'Casey, Erin D'; Seydou Doumbia  
**Cc:** Djibril Sangare; Ousmane Koita; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]  
**Subject:** RE: Laboratory questions

The assays are the same that the NHI/CDC team uses in Monrovia to support ELWA3 (MSF ward). They target L, NP and GP.